US › Healthcare

Mediwound Ltd (MDWD)

US · Healthcare · Biotechnology

$13.35+0.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$3.1M

Revenue YoY

-45.8%

Net profit

$-7.4M

EPS

$-0.77

EPS estimate

$-0.76

Net margin

-239.1%

EPS came in at -0.77 against a street estimate of -0.76 — a miss of 1.3%.

Key statistics

Market cap

$169.3M

Forward P/E

35.0

P/B

4.97

Book value

$2.76

EPS (TTM)

$-2.16

52-week high

$20.03

52-week low

$12.52

50-day MA

$13.92

200-day MA

$16.19

Beta

0.14

Analyst view

Analysts rate Mediwound Ltd a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $29.83.

Shareholding

Insiders

16.53%

Institutions

56.00%

Largest institutional holders

Fund	Stake
Investors Finance Co PLC	6.75%
Yelin Lapidot Holdings Management Ltd	5.87%
Rosalind Advisors, Inc.	5.80%
T. Rowe Price Associates, Inc.	5.50%
BlackRock Inc	3.45%
Meitav Dash Investments Ltd	2.88%
Sphera Funds Management Ltd.	2.12%
Silverberg Bernstein Capital Management LLC	1.77%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mediwound Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.